Academic literature on the topic 'Diabetes Iran'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Diabetes Iran.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Diabetes Iran"
1
Sanjari, Mahnaz, Maryam Aalaa, Mohammad Reza Amini, Neda Mehrdad, Hosein Adibi, Ensieh Nasli Esfahani, and Bagher Larijani. "Conceptual map of diabetes education: necessity of establishing iran diabetes academy." Journal of Diabetes & Metabolic Disorders 18, no. 2 (October 8, 2019): 729–31. http://dx.doi.org/10.1007/s40200-019-00441-y.
Full text
2
Mohammad Alavinia, Seyed, Koorosh Etemad, Alireza Mahdavi, Maryam Omidvar, Sara Imanpour, Rudmilla Rahman, Muhiuddin Haider, and Jared Frank. "Gestational diabetes mellitus in Iran – experience from the National Diabetes Program." International Journal of Pharmaceutical and Healthcare Marketing 6, no. 2 (June 22, 2012): 156–66. http://dx.doi.org/10.1108/17506121211243077.
Full text
3
Ozma, Mahdi Asghari, Jalil Rashedi, Behroz Mahdavi Poor, Ali Vegari, Vahid Asgharzadeh, Hossein Samadi Kafil, Abdolhassan Kazemi, Leyla Sahebi, and Mohammad Asgharzadeh. "Tuberculosis and Diabetes Mellitus in Northwest of Iran." Infectious Disorders - Drug Targets 20, no. 5 (December 9, 2020): 667–71. http://dx.doi.org/10.2174/1871526519666190715142100.
Full textAbstract:
Background: Planning for control of tuberculosis would need to screen and identify individuals susceptible to TB. Due to the weakness of immune system in diabetic patients, it is more likely for them to reactivate latent TB infection. Regarding the increasing number of diabetics in the community, in this study efforts have been made to estimate the frequency of individuals who have tuberculosis and diabetes mellitus (TB-DM) simultaneously, as it could help making preventive decisions to reduce TB in this part of Iran. Materials and Methods: In this study, 329 cases of confirmed TB patients were divided into two groups of diabetic and non-diabetic, then demographic information and clinical variables have been compared between the two groups. Results: Among the examined subjects, 47 patients (14.29 %) had suffered from diabetes mellitus and tuberculosis. All of the DM patients had pulmonary tuberculosis and 87.23% of them were over the age of 50. Conclusion: : Majority of DM-TB patients were over 50 years of age and also more than half of them were women. So it seems that for DM women over the age of 50, to detect tuberculosis, screening tests such as PPD may be necessary.
4
Pishdad, G. R. "Low Incidence of Type 1 Diabetes in Iran." Diabetes Care 28, no. 4 (March 25, 2005): 927–28. http://dx.doi.org/10.2337/diacare.28.4.927.
Full text
5
Beiranvand, Fatemeh, and Mohsen Alizadeh. "Plants for remedies of diabetes mellitus in Iran." Plant Biotechnology Persa 1, no. 1 (November 1, 2019): 36–38. http://dx.doi.org/10.29252/pbp.1.1.36.
Full text
6
Jafarvand, Elnaz, Amin Ataey, and Sare Edalati. "Epidemiology and Death Trends Due to Diabetes in Iran." Quarterly of the Horizon of Medical Sciences 27, no. 2 (April 1, 2021): 198–213. http://dx.doi.org/10.32598/hms.27.2.2764.1.
Full textAbstract:
Aims: Diabetes mortality undergoes a growing trend worldwide that results in reducing life expectancy in society. Diabetes has been a significant health challenge in recent decades and imposed a lot of economic burden on the community. The present study aimed to evaluate the trend of diabetes mortality in Iran over five years. Methods & Materials: The mortality data published by the Ministry of Health and Medical Education has been used in this analytical cross-sectional study. The number and rate of diabetic cases are specified based on age, gender, location, and the death process from 2006 to 2010. Findings: About 54.9% and 45.1% of the deaths occurred in women and men, respectively, with a male to female ratio of 0.82. The highest death rate was observed in individuals aged above 70 and 50-69 years with an average age of 68.1 years. A higher mortality rate was observed in the cities than in the countryside, and 40% of deaths occurred due to non-insulin-dependent (type II) diabetes mellitus. Conclusion: Diabetes mortality has increased from 2006 to 2010. Higher deaths were observed in women and cities. Considering the increasing population of older adults in Iran, diabetes prevention and control interventions can be carried out through screening, planning, and education.
7
Pishdad, G. R. "Age at Diagnosis of Non-Insulin-Dependent Diabetes Mellitus in Southern Iran." Journal of International Medical Research 23, no. 5 (September 1995): 381–85. http://dx.doi.org/10.1177/030006059502300509.
Full textAbstract:
To obtain an estimate of the age at onset of non-insulin-dependent diabetes mellitus in southern Iran, the medical records of the confirmed diabetic patients who attended the diabetes and endocrine clinics in southern Iran from March 1984 to February 1993 were reviewed. The case records of 2566 patients, in whom non-insulin-dependent diabetes mellitus was considered most probable, and who were resident in southern Iran at the time of diagnosis, were studied; they included 1176 (45.8%) men and 1390 (54.2%) women. The age at diagnosis of the disease in men ranged between 18 and 82 years with a mean of 45.6 ± 11.4 (± SD) years, and in women, between 15 and 83 with a mean of 44.3 ± 12.2 (± SD) years. There was no statistically significant sex-related difference in the mean age at diagnosis of non-insulin-dependent diabetes mellitus in these patients. Sex-specific rates showed a female to male ratio of 1.25 to 1. Age-specific rates indicated that non-insulin-dependent diabetes mellitus was most often diagnosed before age 55 and most commonly in the forties.
8
Sarayani, Amir, Arash Rashidian, and Kheirollah Gholami. "Low utilisation of diabetes medicines in Iran, despite their affordability (2000–2012): a time-series and benchmarking study." BMJ Open 4, no. 10 (October 2014): e005859. http://dx.doi.org/10.1136/bmjopen-2014-005859.
Full textAbstract:
ObjectivesDiabetes is a major public health concern worldwide, particularly in low-income and middle-income countries (LMICs). Limited data exist on the status of access to diabetes medicines in LMICs. We assessed the utilisation and affordability of diabetes medicines in Iran as a middle-income country.DesignWe used a retrospective time-series design (2000–2012) and assessed national diabetes medicines’ utilisation using pharmaceuticals wholesale data.MethodsWe calculated defined daily dose consumptions per population days (DDDs/1000 inhabitants/day; DIDs) indicator. Findings were benchmarked with data from Organization for Economic Co-operation and Development (OECD) countries. We also employed Drug Utilization-90% (DU-90) method to compare DU-90s with the Essential Medicines List published by the WHO. We measured affordability using number of minimum daily wage required to purchase a treatment course for 1 month.ResultsDiabetes medicines’ consumption increased from 4.47 to 33.54 DIDs. The benchmarking showed that medicines’ utilisation in Iran in 2011 was only 54% of the median DIDs of 22 OECD countries. Oral hypoglycaemic agents consisted over 80% of use throughout the study period. Regular and isophane insulin (NPH), glibenclamide, metformin and gliclazide were the DU-90 drugs in 2012. Metformin, glibenclamide and regular/NPH insulin combination therapy were affordable throughout the study period (∼0.4, ∼0.1, ∼0.3 of minimum daily wage, respectively). While the affordability of novel insulin preparations improved over time, they were still unaffordable in 2012.ConclusionsThe utilisation of diabetes medicines was relatively low, perhaps due to underdiagnosis and inadequate management of patients with diabetes. This had occurred despite affordability of essential diabetes medicines in Iran. Appropriate policies are required to address the underutilisation of diabetes medicines in Iran.
9
Morovatdar, Negar, Gholamreza Tayebi Nasrabad, Konstantinos Tsarouhas, and Ramin Rezaee. "Etiology of Renal Replacement Therapy in Iran." International Journal of Nephrology 2019 (November 26, 2019): 1–5. http://dx.doi.org/10.1155/2019/5010293.
Full textAbstract:
Introduction. End-stage renal disease (ESRD) is one of the most common life-threatening diseases. In the past two decades, several factors were held responsible as the cause of this condition. The present study aimed to determine the causes of ESRD in the province of Khorasan Razavi, Iran. Materials and Methods. This cross-sectional study was conducted on 2404 ESRD patients who referred to 39 hemodialysis centers in Khorasan Razavi province, Iran, and were registered in the Mashhad University of Medical Sciences (MUMS), between 2000 and December 2018. Sociodemographic data and causes of ESRD were extracted from data registry. Results. The mean age at onset of hemodialysis for 2404 patients was 52.8 ± 16.4 years, and 57.1% of the patients were male. Clinical profile of hypertension (28.3%) and diabetes mellitus (24.8%) were the most common known causes of ESRD in our patients. Hypertension was more prevalent in male patients compared with females (30 vs 25%, respectively) while diabetes was more prevalent in females compared with males (25.4 vs 24.4%, respectively), p=0.009. Educational level was significantly associated with the cause of ESRD (p<0.001). Age of onset of ESRD in hypertensive patients was significantly lower compared with diabetic patients (51.5 ± 16.3 vs 58.28 ± 12.9 years, respectively; p<0.001). Conclusions. In the current study, the most common causes of ESRD were hypertension and diabetes mellitus. Primary prevention of hypertension and diabetes and proper treatment must be considered to reduce the burden of ESRD in Iran.
10
Azizi, F., M. M. Gouya, P. Vazirian, P. Dolatshahi, and S. Habibian. "The diabetes prevention and control programme of the Islamic Republic of Iran." Eastern Mediterranean Health Journal 9, no. 5-6 (March 31, 2003): 1114–21. http://dx.doi.org/10.26719/2003.9.5-6.1114.
Full textAbstract:
Diabetes mellitus has become a monumental problem and a major health concern throughout the world. We report on the programme developed by the Islamic Republic of Iran for control and management of diabetes, which involves screening for type 2 diabetes in adults at risk and a systematic approach for delivery of health care to people with diabetes
Dissertations / Theses on the topic "Diabetes Iran"
1
White, Desley Louise. "Non-transferrin-bound iron and protein glycation in type 2 diabetes." Thesis, University of Plymouth, 2012. http://hdl.handle.net/10026.1/1181.
Full textAbstract:
Background and Methods: The involvement of iron in the risk for, and complications of, type 2 diabetes has generated substantial interest over the past 15 years, initially sparked by an association with raised serum ferritin, and the observation that people with iron overload diseases frequently develop diabetes. Considerable advances have since been made in understanding the effect glucose has on molecules, cells, and tissues; and the role that oxidative stress plays in the development of the pathologies of long-term diabetes. Poorly liganded iron is potentially both a contributor to, and consequence of, these complications. In vitro experiments with glucose-incubated transferrin by earlier workers have demonstrated loss of function with increasing glycation, leading to the suggestion that the failure of this key iron-binding protein may contribute to diabetic pathology, via the presence of redox active non-transferrin-bound iron (NTBI). In vitro glycated transferrin is examined here by ultrafiltration, to assess loss of function and possible oxidative fragmentation. Mass spectrometry is used to identify a range of amino acid glycation sites on in vitro glycated transferrin for the first time. Finally, several groups have previously measured NTBI in people with diabetes, finding little agreement in results. NTBI is measured here in a cohort of people with type 2 diabetes, using a new adaptation of earlier NTBI assays. NTBI is also assessed in pre-dialysis chronic kidney disease (CKD) stages I to III for the first time. Results and Conclusions: Experiments with glycated transferrin in vitro demonstrate oxidative fragmentation, explaining the loss of function reported by earlier groups. In vitro glycated transferrin examined by mass spectrometry reveals a substantial number and range of amino acids subject to glycation. Comparison with in vivo glycated transferrin suggests that many of the in vitro glycation sites are not glycated in vivo, and that there are many oxidized methionine residues which are potential artefacts, or likely to be repaired by methionine sulphoxide reductases in vivo. A study of people with type 2 diabetes finds no direct association between NTBI and protein glycation. Unexpected correlations between NTBI and LDL, and LDL and haemoglobin with increasing protein glycation, are reported for the first time. NTBI is suggested to be iron sourced from haemoglobin or haem, from erythrocyte haemolysis prior to sample collection. In people with pre-dialysis CKD stages I to III no significant difference in NTBI level compared to controls is seen, or correlations with markers of renal function. No link between NTBI and kidney function at this stage of disease is indicated.
2
Aljwaid, Husam O. Dakhil. "Relationships between iron, oxidative stress, glycated proteins and the development of atherosclerosis in Type 2 diabetes." Thesis, University of Plymouth, 2015. http://hdl.handle.net/10026.1/3222.
Full textAbstract:
Hyperglycaemia stimulates a variety of biochemical abnormalities. The area of particular interest in this study is the influence of non-enzymatic glycation of proteins on iron homeostasis, and particularly on non-transferrin-bound iron (NTBI) and its possible relation to atherogenesis in both Type 2 diabetic and obese non diabetic subjects. The link between non-enzymatic glycation of proteins and iron homeostasis, and development of macrovascular disease may be mechanistically different in Type 2 diabetic and obese non diabetic subjects due to a difference in the protein glycation pattern. Because the following in vivo study required storage of samples for up to two years to complete the processing of all the samples, a storage study was carried out using different anticoagulants and addition of reduced glutathione (GSH) to samples to study the effects of storage, thawing and freezing of the samples on the level of malondialdehyde (MDA), a biomarker of lipid peroxidation. This storage study showed that EDTA attenuated the action of lipid oxidation compared with lithium heparin (LiH). A combination of GSH with either EDTA or LiH added more protection from lipid peroxidation in the first week of storage, but due to the thawing and freezing of the sample the action of GSH diminished through its autooxidation, meaning that addition of GSH to samples in the following in vivo study would be useless. An in vivo study was carried out on iron-related parameters in three subject groups: control (non-diabetic, non-obese), Type 2 diabetic and obese non diabetic. Glycated haemoglobin (HbA1C) was strongly correlated with NTBI in the diabetic group. Also the level of NTBI was significantly increased in Type 2 diabetic subjects compared with other groups while the level of total iron was significantly decreased. The study showed a strong positive correlation between NTBI and a biomarker of endothelium dysfunction (E-selectin) in all groups studied. Although it is not possible from the current data to know if there is a causal relationship between these two parameters, it remains a possibility that iron released from its binding sites could initiate oxidative damage to the endothelial cells and begin the process of atherogenesis. Positive correlation at the 90% confidence level between NTBI and a biomarker of inflammation, high sensitivity C-reactive protein, is another indicator in this study of a link between increases in NTBI, inflammation, endothelium dysfunction and atherosclerosis. This study also showed for first time that NTBI is present in higher levels in the plasma of obese subjects compared to controls despite the obese subjects having significantly lower total iron. An in vitro study found that glycation of transferrin half saturated with iron increased with increasing glucose concentration, leading to decreased capacity of transferrin to hold iron and increased release of free iron. Also co-incubation of transferrin half saturated with iron with low density lipoprotein (LDL) and glucose showed oxidation of LDL (measured as MDA). This may be explained by the effect of glycation, leading to release of free iron, which catalyses oxidation of LDL. In addition, glycation of LDL may enhance the oxidation of LDL catalysed by iron. Both studies indicate that the glycation of proteins has a major impact on iron homeostasis leading to release of non-enzymatic glycation and contributing to one of the most common complications of Type 2 diabetes, atherosclerosis.
3
Fernández, Cao José Cándido. "Iron excess and risk of type 2 diabetes mellitus in a prospective cohort of mediterranean population." Doctoral thesis, Universitat Rovira i Virgili, 2016. http://hdl.handle.net/10803/378354.
Full textAbstract:
Antecedents: El consum de ferro hemo i els dipòsits de ferro s'han associat amb el risc de diabetis mellitus tipus 2 (DMT2) en cohorts nord-americans, xineses, i del nord d'Europa, però aquestes relacions no han estat estudiades en poblacions del sud d'Europa.
Objectius: Avaluar, prospectivament, l'efecte de la ingesta elevada de ferro i l'estat elevat de ferro en l'aparició de la DMT2 en població mediterrània adulta, i estudiar la relació entre l'estat del ferro i l'osteocalcina.
Mètodes: Els participants van ser homes i dones de 55 a 80 anys de l'estudi PREDIMED. La DMT2 va ser diagnosticada utilitzant els criteris de l'ADA. Es van recollir dades sociodemogràfiques, antropomètriques, d'estil de vida, estat de ferro, perfil lipídic, metabolisme de la glucosa i inflamació.
En un estudi observacional en 1.073 persones, 131 diabètics incidents, es va avaluar l'associació entre la ingesta de ferro i la DMT2. Es va analitzar transversalment en 423 subjectes la relació entre l'estat de ferro i l'osteocalcina. Finalment, un estudi casos-control niat va ser dissenyat per avaluar l'associació entre l'estat de ferro, mesurat mitjançant la ferritina sèrica (FS) i el receptor soluble de transferrina (sTfR), i el risc de DMT2 en 459 participants, 153 diabètics incidents.
Resultats: Es va trobar que una ingesta elevada de ferro hemo augmenta el risc de DMT2 en un 30%. A més, els valors de FS>257μg/L en homes i >139μg/L en dones es van associar amb DMT2. També es va trobar associació entre la ràtio sTfR: ferritina i la DMT2, però no amb el sTfR. Tant la FS com el sTfR es relacionen amb l'osteocalcina.
Conclusions: En una població mediterrània adulta d'alt risc cardiovascular, una ingesta elevada de ferro hemo i uns dipòsits elevats de ferro augmenten el risc de DMT2. La relació entre l'estat de ferro i l'osteocalcina és controvertida.Antecedentes:El consumo de hierro hemo y los depósitos de hierro se han asociado con el riesgo de diabetes mellitus tipo 2 (DMT2) en cohortes estadounidenses, chinas, y del norte de Europa, sin embargo estas relaciones no han sido estudiadas en poblaciones del sur de Europa. Objetivos:Evaluar, prospectivamente, el efecto de la ingesta elevada de hierro y el estado elevado de hierro en la aparición de la DMT2 en población mediterránea adulta, y estudiar la relación entre el estado del hierro y la osteocalcina. Métodos:Los participantes fueron hombres y mujeres de 55 a 80 años del estudio PREDIMED. La DMT2 fue diagnosticada utilizando los criterios de la ADA. Se recogieron datos sociodemográficos, antropométricos, de estilo de vida, estado de hierro, perfil lipídico, metabolismo de la glucosa e inflamación. En un estudio observacional en 1.073 personas, 131 diabéticos incidentes, se evaluó la asociación entre la ingesta de hierro y la DMT2. Se analizó transversalmente en 423 sujetos la relación entre el estado de hierro y la osteocalcina. Finalmente, un estudio casos-control anidado fue diseñado para evaluar la asociación entre el estado de hierro, medido mediante la ferritina sérica (FS) y el receptor soluble de transferrina (sTfR),y el riesgo de DMT2 en 459 participantes, 153 diabéticos incidentes. Resultados:Se encontró que una ingesta elevada de hierro hemo aumenta el riesgo de DMT2 en un 30%. Además, los valores de FS>257μg/L en varones y >139μg/L en mujeres se asociaron con DMT2. También se encontró asociación entre el ratio sTfR:ferritina y la DMT2, pero no con el sTfR. Tanto SF como el sTfR se relacionan con la osteocalcina. Conclusiones:En una población mediterránea adulta de alto riesgo cardiovascular, una ingesta elevada de hierro hemo y unos depósitos elevados de hierro aumentan el riesgo de DMT2. La relación entre el estado de hierro y la osteocalcina es controvertida.
Background: The intake of haem iron intake as well as body iron stores have been associated with the risk of developing type 2 diabetes mellitus (T2DM) in U.S., Chinese, and northern European cohorts, however these relationships have not been studied in southern European populations. Objectives: To assess, prospectively, the effect of elevated dietary iron intake and body iron status on the onset of T2DM in an adult Mediterranean population, and to evaluate the relationship between iron status and osteocalcin as a potential mechanism for explaining iron-induced T2DM. Methods: Participants were men and women aged 55 to 80 years from the PREDIMED study. New-onset T2DM during follow-up was diagnosed using the criteria of the American Diabetes Association. Socio-demographic, anthropometric, lifestyle, dietary intake, iron status, lipid profile, glucose metabolism, inflammation variables were collected at baseline. An observational cohort study was conducted in 1,073 individuals, 131 incident diabetics, to assess the association between iron intake and T2DM. A cross-sectional study was carried out in 423 subjects to evaluate the relationship between iron status and osteocalcin. Finally, a prospective nested case-control study was design to assess the association between body iron status, measured as serum ferritin (SF) and soluble transferrin receptor (sTfR) and its ratio, with T2DM in 459 participants, 153 incident diabetics. Results: We found that a high haem iron intake increases the risk of T2DM by 30%. In addition, SF values >257µg/L in males and >139µg/L in females were associated with T2DM. We also found association between sTfR:ferritin ratio and T2DM, but not with sTfR. Both SF and sTfR were related to osteocalcin. Conclusions: In an adult Mediterranean population at high cardiovascular risk, high dietary haem iron and body iron stores increase the risk of T2DM after adjustment for potential confounding variables. The relationship between iron status and serum osteocalcin levels is controversial.
4
Dubreil, Chloé. "Nanoparticules tolérogènes pour l’administration d’un auto-antigène des cellules bêta dans le diabète auto-immun Tolerogenic iron oxide nanoparticles in type 1 diabetes: biodistribution and pharmacokinetics studies in nonobese diabetic mice Tolerogenic nanoparticles boost regulatory B cells to reverse autoimmune diabetes." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCB141.
Full textAbstract:
Les maladies auto-immunes chroniques sont la conséquence de la reconnaissance par le système immunitaire d'auto-antigènes comme élément étranger, entraînant une destruction des tissus et organes cibles. Le diabète de type 1 (DT1), la maladie auto-immunes chronique la plus courante, est caractérisé par un insuffisance en insuline due à la destruction sélective des cellules bêta productrices d'insuline. Lors de l'apparition des signes cliniques, plus de 70% de la masse des cellules bêta peut être détruite. Par conséquent, le diagnostic précoce est un objectif majeur afin de limiter l'agression auto-immune, et de créer une fenêtre thérapeutique pour améliorer la survie ou la régénération des cellules bêta. Les approches spécifiques d'antigène (Ag) sont attrayantes du fait de la spécificité de leur mécanisme limité à l'organe cible. Cependant, bien que la prévention du développement du diabète via l'utilisation d'autoantigènes chez la souris non obèse diabétique (NOD) ait été étudiée, les essais cliniques chez l'homme ont produit des résultats décevants. Par conséquent, des approches combinant deux stratégies thérapeutiques pourraient être envisagées. Une stratégie potentielle consiste à co-administrer des auto-antigènes à un traitement antiinflammatoire afin que les deux traitements soient présentés au même moment dans l'environnement des cellules immunitaires auto-réactives. La première partie de ce travail consiste à caractériser physico-chimiquement le vecteur transportant les deux traitements afin d'optimiser la charge médicamenteuse tout en maintenant la biocompatibilité et la stabilité du véhicule de délivrance. Ainsi, des nanoparticules (NPs) d'oxydes de fer superparamagnétiques (USPIO) ont été fonctionnalisées en surface avec des polymères de phosphonate polyéthylène glycol (USPIO-PEG). Les fonctions acide carboxylique ont été utilisées pour lier par covalence un autoantigène DT1. Une molécule antiinflammatoire est piégée par interactions hydrophobes dans les chaines de polymères. Après avoir mis en évidence l'internalisation cellulaire et la non toxicité sur des cellules dendritiques dérivées de la moelle osseuse murine (BMDCs), nous avons entrepris des études de biodistribution et de pharmacocinétique en utilisant le modèle NOD qui partage de nombreuses caractéristiques avec la pathologie humaine. Différentes techniques ont été utilisées à savoir l'IRM, l'histologie et de la magnétométrie sur organe isolé. Les NPs s'accumulent préférentiellement dans le pancréas des souris NOD via un effet de perméabilité et de rétention accrue (EPR effect). Cette bioaccumulation pourrait être exploitée pour la délivrance ciblée du traitement. La deuxième partie du travail consiste à évaluer l'effet thérapeutique de telles nanoparticules tolérogènes sur des souris diabétiques NOD. Des souris diabétiques ont été injectées par voie intraveineuse. Les souris contrôles traitées avec des nanoparticules « nues » ont atteint un niveau de glucose sanguin de 600 mg/dL, considéré comme point limite de l'expérience, en 4-6 jours. Les nanoparticules portant soit la molécule tolérogène soit l'autoantigène ont retardé la progression du diabète jusqu'à 40 jours. Les NP complètes quant à elles, ont montré des effets synergiques. En effet, 50% des souris traitées étaient encore en vie 65 jours après l'apparition de la maladie, et deux souris montrèrent une normoglycémie stable plus de 300 jours après l'apparition de la pathologie. Les nanoparticules tolérogènes induisent une splénomégalie principalement due à la prolifération des lymphocytes B. Les cellules B stimulées par des nanoparticules sécrètent des cytokines anti-inflammatoires, à savoir IL-10 et TGF-bêta. Des cellules B similaires sont également produites in vitro lors de l'incubation avec des nanoparticules. Notre stratégie au potentiel thérapeutique prometteur pourrait être appliquée, en utilisant des antigènes appropriés, à un plus large éventail de maladies auto-immunesChronic autoimmune diseases are the consequence of self-antigens recognition as foreign by the adaptive immune system, resulting in inflammation and potential destruction of targeted tissues and organs. Type 1 diabetes (T1D) is one of the most common chronic autoimmune diseases. It is characterized by insulin deficiency due to selective destruction of insulin-producing beta-cells. At clinical onset, more than 70% of beta-cell mass can be destroyed. Consequently, early diagnosis is a major objective in order to avoid, limit or reverse autoimmune aggression, and to create opportunities for strategies enhancing beta-cell survival or regeneration. Antigen (Ag)-specific approaches are appealing because their effects are expected to be limited to cells expressing the chosen antigen, ideally the target organ. However, while treatment with beta -cell Ags can prevent disease in the model of the Non-Obese Diabetic (NOD) mouse, clinical trials in humans have produced disappointing results. Consequently, combinatorial approaches may be required for reversal and prevention of T1D. A potential strategy is to associate self-antigens with signals inducing a tolerogenic phenotype. Co-delivery ensures that both compounds get delivered at the same time and presented in the same cellular environment to auto-reactive immune cells. The first part of this work consisted in undertaking a thorough physicochemical characterization of a new drug vector, aiming to establish quantitative methods to optimize drug loading while maintaining biocompatibility and stability of the delivery vehicle. In this work, 9nm Ultra-small superparamagnetic iron-oxide (USPIO) nanoparticles were surface functionalized with phosphonate polyethylene glycol molecules (USPIO-PEG). Carboxylic acid functions were used to covalently bind a T1D autoantigen. PEG brush allows for the co-packaging of hydrophobic tolerogenic drug molecules, trapped between PEG chains through hydrophobic interactions. We carefully characterized protein and tolerogenic drug loading, and studied cell labeling, toxicity, integrity of loaded protein and tolerogenic drug, and activity of our nanoplatform on murine Bone Marrow Derived Dendritic Cells (BMDCs). We undertook biodistribution and pharmacokinetics studies using the NOD model that shares numerous features with human T1D. Biokinetic studies were performed both qualitatively using MRI 7T and histological Perls staining analyses and quantitatively using magnetometry for NP quantification. USPIO accumulate preferentially in NOD mice pancreas via Enhanced Permeability retention (EPR) effect thus, allowing us to distinguish pre-diabetic mice from non-diabetic controls. This result suggests that vascular leakage could be exploited for NP bioaccumulation, for therapeutic agent delivery and for imaging using MRI agents to monitor treatment. The second part of the work consisted in evaluating the therapeutic effect of such tolerogenic nanoparticles (NPS) on NOD diabetic mice. Diabetic mice were injected intravenously at diabetes onset. USPIO-PEG and vehicle treated mice reached 600mg/dL blood glucose level, considered limit for sacrificing mice, within a couple of days. NPs carrying either the tolerogenic drug or the autoantigen delayed diabetes progression up to 40 days. Complete NPs showed synergistic effects. In fact, 50% of treated mice were still alive 65 days after disease onset, and two mice reverted to stable normoglycemia for more than 300 days. To identify the underlying mechanism, the immune response to NPs in lymphoid organs was investigated. It was found that tolerogenic NPs induce splenomegaly mainly due to B cell proliferation. NP-stimulated B cells secrete anti-inflammatory cytokines namely IL-10 and TGF-beta. Similar B cells could be produced in vitro upon incubation of with NPs. Our strategy has promising therapeutic potential and could be applied, using relevant antigens, to a wider range of autoimmune diseases
5
Olivatto, Gabriela Marsola. "Caracterização sociodemográfica e clínica de pacientes com talassemia maior e diabetes mellitus de um centro de referência no interior de São Paulo." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/22/22132/tde-28112017-150253/.
Full textAbstract:
A maior expectativa de vida dos pacientes com talassemia maior, as repetidas transfusões de concentrado de hemácias como parte do tratamento, podem ocasionar maior deposição de ferro nos órgãos, e consequentemente, as comorbidades. Dessa forma, dentre as comorbidades endócrinas, temos o diabetes mellitus como uma das principais, sendo necessário conhecer o panorama em nossa realidade. O estudo tem como objetivos determinar a prevalência do diagnóstico de diabetes em pacientes com talassemia maior, caracterizar e comparar os pacientes com talassemia maior, e diabetes mellitus, segundo as variáveis sociodemográficas e clínicas.Trata-se de um estudo descritivo e transversal, realizado em um centro de referência no tratamento de talassemia do interior paulista. A amostra foi constituída por 31 pacientes com talassemia maior. Para a coleta de dados utilizou-se um instrumento subdividido em duas partes. Os dados sociodemográficos e clínicos foram obtidos por meio de entrevista dirigida e os resultados de exames laboratoriais pelo prontuário eletrônico do paciente, no período de junho a agosto de 2015. Os dados foram digitados e importados para o programa SPSS for Windows, versão 17.0 e submetidos à análise estatística descritiva. O projeto foi aprovado pelo Comitê de Ética em Pesquisa da Escola de Enfermagem de Ribeirão Preto da Universidade de São Paulo (CEP/EERP-USP), sob Protocolo nº 41912415.3.0000.5393. Dos 31 pacientes com talassemia maior, 5 (16,1%) tinham diabetes mellitus. Em relação as variáveis sociodemográficas, não houve diferenças na distribuição dos pacientes entre os sexos, a maioria eram solteiros e cursaram até o ensino médio completo. A idade variou de cinco a 48 anos, com média de 24,9 anos de idade, a maioria recebia até 10 salários mínimos, eram estudantes e possuíam carteira de trabalho assinada. No que tange às variáveis clínicas, temos que o tratamento utilizado predominante foi o quelante oral deferasirox, e naqueles pacientes com diabetes, além do deferasirox, a maioria utilizava a insulina. O esquema transfusional predominante foi o de 15 a 22 dias. O índice de massa corpórea foi classificado como eutrófico e a pressão arterial, considerada ótima para a maioria dos pacientes. Quanto aos achados dos exames laboratoriais, os pacientes com diabetes e talassemia apresentaram valores alterados de glicemia de jejum e transaminase, já os pacientes sem diabetes apresentaram valores alterados de ferritina sérica. No que se refere aos achados dos exames de imagem, nenhum paciente com diabetes e Talassemia maior apresentou massa óssea adequada, o que reforça a importância de seu monitoramento. Destaca-se o aumento de sobrecarga cardíaca para os pacientes com diabetes e talassemia. Para os pacientes com talassemia e sem diabetes, a maioria apresentou grave sobrecarga de ferro hepático na ressonância magnética do fígado, enquanto para a maioria dos pacientes com diabetes foi considerado normal. Dessa forma, conhecer as características clínicas dos pacientes com talassemia maior e diabetes permite subsidiar a assistência de enfermagem qualificada e contribuir com a saúde dos pacientes com condições crônicas. Contudo, os nossos achados corroboram com as taxas de prevalência de diabetes em pacientes com talassemia maior encontradas na literatura nacional e internacionalThe longer life expectancy of patients with thalassemia major, repeated red blood cell transfusions as part of the treatment, may lead to increased iron deposition in the organs, and consequently, comorbidities. Thus, among the endocrine comorbidities, we have diabetes mellitus as one of the main ones, being necessary to know the panorama in our reality. The aim of the study was to determine the prevalence of diabetes in patients with thalassemia major and to characterize and compare patients with thalassemia major, and diabetes mellitus, according to sociodemographic and clinical variables.This is a descriptive and cross-sectional study, carried out in a reference center in thalassemia treatment of São Paulo countryside. The sample consisted of 31 patients with thalassemia major. For data collection, an instrument was divided into two parts. Sociodemographic and clinical data were obtained by means of a directed interview and the laboratory tests results by the patient\'s electronic record, from June to August 2015. Data were loaded into SPSS for Windows software, version 17.0 and submitted to descriptive statistical analysis. The project was approved by the Research Ethics Committee of the University of São Paulo at Ribeirão Preto College of Nursing (CEP / EERP-USP) under Protocol No. 41912415.3.0000.5393. Of the 31 patients with thalassemia major, 5 (16,1%) had diabetes mellitus. Regarding the sociodemographic variables, there were no differences in the distribution of the patients between the sexes, most of them were single and enrolled in high school. The age ranged from five to 48 years, with a mean of 24,9 years of age, the majority received up to 10 minimum wages, were students and had a work contract. Regarding the clinical variables, we have that the predominant treatment was the oral chelator deferasirox, and in those patients with diabetes, in addition to deferasirox, the majority used insulin. The predominant transfusion regimen was 15 to 22 days. Body mass index was classified as eutrophic and blood pressure was considered optimal for most patients. Regarding the laboratory findings, patients with diabetes and thalassemia had altered values of fasting glycemia and transaminase, whereas patients without diabetes had altered values of serum ferritin. Regarding imaging exams findings, no patient with diabetes and major thalassemia presented adequate bone mass, which reinforces the importance of their monitoring. The increase in cardiac overload for patients with diabetes and thalassemia stands out. For patients with thalassemia and without diabetes, the majority had severe hepatic iron overload in the magnetic resonance imaging of the liver, while for most patients with diabetes it was considered normal. Thus, knowing the clinical characteristics of patients with thalassemia major and diabetes allows subsidizing qualified nursing care and contributing to the health of patients with chronic conditions. However, our findings corroborate the prevalence rates of diabetes in patients with thalassemia major found in the national and international literature
6
Steed, Kevin Sage. "Alzheimer's Disease and Diabetes: A Transgenic Mouse Model in Behavior, MRI, and Cells." BYU ScholarsArchive, 2018. https://scholarsarchive.byu.edu/etd/7460.
Full textAbstract:
Alzheimer's disease (AD) is the most common form of dementia, afflicting almost 5 million patients in the US, and impacting millions more, financially, physically and emotionally. Coming in as the 6th leading cause of death in the US, and showing no signs of slowing its annually increasing rates, the world is in desperate need of improved understanding of the disease's multifaceted pathogenesis and progression, more accurate forms of detection and diagnosis, and more effective prevention and treatment. While many are focused on the noble pursuit of understanding the genetic contributions to the appearance of the pathological amyloid beta (Aβ)) plaques and tau tangles seen in AD, the majority of cases are not explained by genes or allele risk. Instead environmental, dietary and lifestyle contributors may be the key to understanding, diagnosing and treating this awful disease. Diet especially may impact the body's ability to regulate oxidative stress, which will cause damage within the cell and lead to further dysregulation of iron storage and metabolism. Iron storage is heavily monitored through cellular mechanisms, and the way in which the body reacts involves creation of the Aβ plaques and tau tangles as receptacles for the molecule it has deemed as the cause of the problem, iron. We have aptly named our theory, the Iron Hypothesis, and in the following document will outline the evidence for this hypothesis, and the experiments designed and performed to prove it.First, we aimed to examine the impacts that various treatments would have on a transgenic in-vivo model, examining the cohorts' behavior over several time points. We report a significant difference in the behavioral measures of time, distance, errors and failed trials in the radial arm maze existed between genotype, treatment and sex of the mice. Tissue of the experimental mice was collected, but will be processed and analyzed at a later date.Secondly, we aimed to examine the same cohorts of the in-vivo mouse model for minute anatomical changes that took place over the course of the aforementioned behavioral trials using novel MRI scanning sequences sensitive to the low levels of iron build up. We report significant differences in the UTE scan measures for our western diet treatment at TE's of 1.2ms. Additionally, further investigation and optimization of the protocol may be required to further expand the findings.
7
Suarez, Ortegon Milton Fabian. "Markers of iron status and cardiometabolic disease risk : an exploration of the association based on cross-sectional and prospective studies in multiple populations." Thesis, University of Edinburgh, 2017. http://hdl.handle.net/1842/31470.
Full textAbstract:
The aim of this thesis is to contribute to the understanding of iron metabolism, as a factor associated with cardiometabolic risk, by undertaking secondary data analyses. The objectives were to identify gaps in existing knowledge in terms of populations studied and alternative iron markers, and to attempt to fill the gaps with additional analyses and interpretation. Serum ferritin was the most widely available measure of iron status but the role of serum transferrin and soluble transferrin receptor (sTfR) levels was considered where available. I have taken a life-course approach with analyses in childhood and adulthood, and have included both intermediate factors such as the metabolic syndrome (MetS), and disease diagnoses of diabetes and cardiovascular disease as outcomes. Chapter one presents a review of empirical research literature on the relationship between iron metabolism and cardiometabolic risk, concepts surrounding iron markers and the study outcomes. This chapter also describes the gaps in understanding the iron-cardiometabolic risk relationship, which are subsequently explored in chapters two to six. Chapter two explores the link between serum ferritin and transferrin and MetS in cross-sectional and prospective studies of 725 Spanish children and 567 Chilean adolescents. I found associations between both ends of the ferritin distribution and MetS or glucose metabolism markers in different paediatric populations. For instance, whereas in the Spanish children there was a decrease of 0.02 SD units in the change of MetS score over time for every SD unit increase in ferritin, in the Chilean male adolescents being in the highest tertile of ferritin (v. the lowest) was associated with an increase of 0.25 SD units of MetS score. Furthermore, sustained high ferritin levels at various time points and gradual increase of ferritin during childhood were associated with higher MetS score in adolescence. The third chapter describes the association between serum ferritin status and MetS in adults in two cross-sectional studies of Scottish populations (2,047 individuals from Shetland Islands and 8,563 subjects from the Scottish Health Surveys (SHeS) 1995- 1998). I also examined the overall association between ferritin, MetS and each MetS component in adults, by conducting a meta-analysis and investigating potential relevant sources of heterogeneity for the association. Interestingly, ferritin levels were positively associated with MetS in the Scottish populations, but the association was not independent of the effect of covariates, mainly body mass index (BMI) and transaminase levels [Men Odds ratio (OR) 95% confidence interval (CI) 1.43(0.83- 2.46); Postmenopausal women OR (95%CI) 1.09(0.62-1.90); Premenopausal women OR (95%CI) 1.02(0.42-2.46), P > 0.05]. The meta-analysis supported this finding by describing hepatic injury markers and BMI as the major attenuating factors of the ferritin-MetS association. Chapter four investigates the association between sTfR or ferritin, and MetS in 725 Croatian adults in a cross-sectional study. There was no evidence of an association between sTfR and MetS [Men OR (95%CI) 1.35(0.90-2.02); Postmenopausal women OR (95%CI) 0.73(0.47-1.15); Premenopausal women OR (95%CI) 0.87(0.66-1.17), P > 0.05]. In contrast serum ferritin, was positively and independently associated with MetS in men and postmenopausal women (P < 0.05) [Men OR (95%CI) 1.78(1.31- 2.42); Postmenopausal women OR (95%CI) 1.71(1.12-2.62); Premenopausal women OR (95%CI) 1.24(0.85-1.80)]. These contrasting results suggest that different iron markers reflect different physiological processes other than iron metabolism. Chapter five evaluates the longitudinal association between serum ferritin and several cardiometabolic disease outcomes (CMDs) in the nationally representative SHeS 1995 and 1998 (n = 6,497). I found an independent positive longitudinal association between ferritin and cerebrovascular disease (CEVD), which was strengthened by using higher cut-points for increased ferritin [higher v. lowest sextile fully adjusted Hazard ratio(HR) 95%CI 2.08 (1.09-3.94), P=0.024], and a not significant association with coronary heart disease (CHD) after adjustment for covariates. My analyses confirmed the widely established association with type 2 diabetes (T2D) [whole sample fully adjusted HR 95% CI 1.59(1.10-2.34), P=0.006], even with serum ferritin within the normal range. The above set of observations confirm ferritin as biomarker mainly related to the development of T2D and identifies the need to investigate the association between ferritin and CEVD in other populations. Chapter six investigates whether ferritin is associated with risk for cardiovascular complications among people with T2D using cross-sectional study designs in two populations with differing baseline cardiovascular risk (Spanish study SIDIAP n=38,617) and (Edinburgh Type 2 Diabetes Study (ET2DS) n= 821) with additional analysis of follow-up data for ET2DS. Interestingly, ferritin levels were negatively associated with prevalence of cardiovascular disease, mainly CHD, in people with T2D in both studies [ET2DS OR (95%CI): 0.80(0.67-0.96), P=0.020; SIDIAP study: 0.85(0.83-0.88), P < 0.001). Ferritin was also negatively associated with incident cardiovascular disease in ET2DS: HR 95% CI: 0.39(0.16-0.93), P=0.035. Therefore, the association between iron status and CMD risk in people with T2D appears to differ from that in general populations in which a positive association has been more commonly described. In conclusion, serum ferritin is associated with cardiometabolic risk in different ways in a variety of populations. Inconsistent associations for other iron markers suggest that iron biomarkers reflect factors other than iron homeostasis that influence cardiometabolic risk. The association between iron markers and MetS appears to differ between populations. This thesis illustrates the complex relationship between iron metabolism markers, MetS and CMD, and identifies the need for further research on the topic in order to extend knowledge about pathophysiology and the potential for measures of iron status as biomarkers for CMD.
8
Virasith, Helene. "Long-chain polyunsaturated fatty acids and iron status in infants of gestational diabetic mothers." Thesis, McGill University, 2010. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=86758.
Full textAbstract:
Arachidonic acid (AA), docosahexaenoic acid (DHA) and iron are important nutrients for infants and are hypothesized to be compromised in infants of diabetic mothers (IDM). The objective of this study was to compare AA, DHA and iron status in IDM with those measured in infants of non-diabetic mothers born both appropriate for gestational age (AGA) and large for gestational age (LGA); and to determine if infants that have compromised AA and DHA status also have a compromised iron status. Analyses of covariance between AA, DHA and iron revealed that AA in infants was positively correlated with iron status overall, but this was not the case for DHA. In IDM, the relationship between iron and AA status was more pronounced. These data suggest iron is linked to AA status in all infants and that IDM are at higher risk for low AA status and consequently impaired development.L'acide arachidonique (AA), l'acide docosahexaénoïque (DHA) et le fer sont d'importants nutriments pour le nouveau-né. Il semblerait que leurs niveaux sont compromis chez les enfants de mères diabétiques (EMD). L'objectif de cette étude est de comparer les niveaux d'AA, de DHA et de fer chez les EMD avec ceux mesurés chez les enfants de mères non diabétiques qui sont nés avec un poids moyen ou gros pour l'âge gestationnelle pour déterminer si les niveaux de gras insaturés à longues chaînes et de fer sont tous les deux amoindris chez l'enfant. L'analyse de covariance entre le fer et les gras insaturés a montré que le niveau de fer est positivement corrélé avec le niveau d'AA mais pas avec celui de DHA. Chez les EDM, le lien entre le fer et l'AA est encore plus marquant. Ces résultats suggèrent que le niveau de fer est relié avec le niveau d'AA chez tous les nouveau-nés et qu'il y a un plus grand risque chez les EDM d'avoir un niveau d'AA amoindri et par conséquent de souffrir de problèmes de croissance.
9
Kuek, Conchita Maria. "Hereditary haemochromatosis and the C282Y genotype : implications in diagnosis and disease." University of Western Australia. School of Surgery and Pathology, 2003. http://theses.library.uwa.edu.au/adt-WU2004.0024.
Full textAbstract:
[Truncated abstract. Please see the pdf format for the complete text.] The discovery of the C282Y mutation and its role in the development of hereditary haemochromatosis has allowed a greater understanding into the effects of iron overload and its involvement in other conditions such as diabetes and heart disease. It has also allowed the better classification of heterozygotes, who were previously only diagnosed through the use of family studies. There are however, areas of conflict between phenotyping and genotyping methods. My research involved examining the relationship between Haemochromatosis and certain diseases such as diabetes and heart disease; genotyping versus phenotyping discrepancies and the possible interaction of secondary mutations. In Chapter 3 a population study was undertaken with the aim of comparing genotyping versus phenotyping methods as well as increasing general practitioner awareness regarding hereditary haemochromatosis and its diagnosis. It was determined that a minimum of 5000 subjects would be required to give the study sufficient power. Individuals were to be between the ages of 20—40 years, and thus presumably presymptomatic. Participation was entirely voluntary and a consent form was to be signed. Recruitment of subjects proved to be difficult and there was a selective bias towards individuals already displaying symptoms of haemochromatosis. In total less than a 100 subjects were recruited for the study. There were several issues encountered in the implementation of this study. Firstly the number of GPs participating was probably insufficient to recruit the subjects required. A more extensive campaign was probably required to enroll more GPs. Secondly it is very difficult for a busy GP to find the time necessary to explain the study to each of his patients and to get them to sign the consent form. Finally a bias developed in some of the requests. The subjects participating in this study were supposed to be random but in many cases the GPs had enrolled them in the study because they had symptoms of iron overload. In effect the biggest obstacle this study faced was the recruitment of subjects. Due to the small number of subjects little statistical data could be obtained from this study. It was noted, however, that genotyping methods detected two individuals who were homozygous for the C282Y mutation. Both also had increased transferrin saturation levels. Phenotyping detected 5 individuals with increased transferrin saturation. The three others detected via phenotyping were C282Y heterozygotes. Haemochromatosis has long been though to be related to the development of diabetes due to the effect of iron overload on the pancreas. If this is so it would be logical to assume that the prevalence of haemochromatosis would be higher in a diabetic population. Chapter 4 examined the possibility that diabetics have a higher frequency of the C282Y mutation. A population group consisting of 1355 diabetics was genotyped for the C282Y mutation and iron studies were performed on all heterozygotes and C282Y homozygotes. Initial findings indicated that there was a significant difference between the diabetic and control population. However, this finding was the opposite of what was expected, there seemed to be a decreased frequency of the Y allele in the diabetic population rather than an increased one. The control and diabetic populations were not matched in terms of ethnicity. The removal of the ethnic bias in the diabetic population altered the statistics so there was no longer a significant difference between the two groups. This study highlighted the importance of using appropriate control populations as comparison groups. The final results of the study indicated that there was no significant difference between the diabetic population and the control population. This would seem to indicate that there is not an increased occurrence of the C282Y mutation in the diabetic population when compared to the control group. Chapter 5 considered the possible association between C282Y heterozygosity and cardiovascular disease as well as the potential for early mortality. Several recent studies have indicated that C282Y heterozygosity may be a risk factor for the development of atherosclerosis, possibly on the basis of increased iron loading. Using a control population and a population of individuals with known coronary events the incidence of the C282Y mutation was compared against other risk factors. C282Y heterozygosity did not appear to be a risk factor for atherosclerosis. There was however, a statistically significant link between increased ferritin in women and carotid plaques. A population of elderly women was genotyped in order to examine the effects of C282Y heterozygosity on longevity. The first hypothesis addressed in chapter 5 was that C282Y heterozygosity was a risk factor for the development of coronary heart disease.
10
GONÇALVES, RODOLFO D. M. R. "Avaliação de micronutrientes e sua influência no metabolismo secundário de Bidens pilosa e Salvia officinalis, plantas usadas no tratamento de diabetes." reponame:Repositório Institucional do IPEN, 2015. http://repositorio.ipen.br:8080/xmlui/handle/123456789/26385.
Full textAbstract:
Submitted by Claudinei Pracidelli (cpracide@ipen.br) on 2016-06-22T13:06:23Z
No. of bitstreams: 0Made available in DSpace on 2016-06-22T13:06:23Z (GMT). No. of bitstreams: 0
Dissertação (Mestrado em Tecnologia Nuclear)
IPEN/D
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
Books on the topic "Diabetes Iran"
1
Rogers, Thomas R., and Elizabeth M. Johnson. Mucoraceous moulds. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0018.
Full textAbstract:
The mucoraceous moulds are members of the order Mucorales and comprise a number of genera within which are species that typically cause life-threatening infections in immunocompromised hosts, but are also pathogens of patients with diabetes mellitus or burns, or following traumatic injuries or near-drowning incidents, and in iron overload. Clinical presentations may be of rhinocerebral, pulmonary, cutaneous, or disseminated disease. Once established at its initial focus, the infection can progress rapidly. Diagnosis is challenging because this is a relatively rare disease, cultures from sites of infection may be negative, and few biomarkers exist to aid laboratory diagnosis. Histopathological examination of infected tissue is useful in diagnosis. Clinicians should have a high level of suspicion when immunocompromised patients present with sinus infection, facial swelling, orbital bone erosion, nodular lung infiltration, or necrotic skin eschars. The only currently available antifungal agents with evidence of clinical utility in mucormycosis are amphotericin B, posaconazole, and isavuconazole.
Book chapters on the topic "Diabetes Iran"
1
Moghaddam-Banaem, Lida. "Maternal Diabetes in Pregnancy: Iran Perspectives." In Nutrition and Diet in Maternal Diabetes, 71–76. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56440-1_7.
Full text
2
Sarraf-Zadegan, Nizal, and Firoozeh Sajady. "Hypertension and Diabetes Situation in the Eastern Mediterranean Region: With Special Reference to Iran." In Progress in Experimental Cardiology, 451–72. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0455-9_33.
Full text
3
Mahdavi, Atena, Sajjad Moradi, Gholamreza Askari, Bijan Iraj, Thozhukat Sathyapalan, Paul C. Guest, Mohammad Bagherniya, and Amirhossein Sahebkar. "Effect of Curcumin on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review of Randomized Clinical Trials." In Studies on Biomarkers and New Targets in Aging Research in Iran, 139–49. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-56153-6_8.
Full text
4
John, W. Garry, and Tara Wallace. "Diabetes and Iron-Deficiency Anaemia." In HbA1cin Diabetes, 65. Oxford, UK: Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444320343.ch37.
Full text
5
Hininger-Favier, Isabelle, Jean-Marc Moulis, and Jean-Marc Ayoubi. "Iron and Oxidative Stress in Gestational Diabetes." In Nutrition and Diet in Maternal Diabetes, 479–91. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56440-1_36.
Full text
6
Cai, Lu. "Role of Iron in the Pathogenesis of Diabetes and Metabolic Syndrome." In Metabolic Syndrome and Neurological Disorders, 335–61. Chichester, UK: John Wiley & Sons Ltd, 2013. http://dx.doi.org/10.1002/9781118395318.ch21.
Full text
7
Khuttar, Alaa Musa, Karim Al-Jeboury, and Kevin Mcdonald. "Mobile Phone Technologies and Diabetes: a Project for Self-Management and Education." In Reimagining Research for Reclaiming the Academy in Iraq: Identities and Participation in Post-Conflict Enquiry, 79–87. Rotterdam: SensePublishers, 2012. http://dx.doi.org/10.1007/978-94-6091-897-1_7.
Full text
8
Mandal, Sacira. "Association Between Serum Concentrations of Free Fatty Acids with Free Iron in Type 2 Diabetes." In IFMBE Proceedings, 423–32. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73909-6_48.
Full text
9
Gurney, Travis O., Patrick J. Oliver, Sean M. Sliman, Anita Yenigalla, Timothy D. Eubank, Drew M. Nassal, Jiaxing Miao, Jing Zhao, Thomas J. Hund, and Narasimham L. Parinandi. "Hyperglycemic Oxoaldehyde (Glyoxal)-Induced Vascular Endothelial Cell Damage Through Oxidative Stress Is Protected by Thiol Iron Chelator, Dimercaptosuccinic Acid – Role of Iron in Diabetic Vascular Endothelial Dysfunction." In Cardiovascular Signaling in Health and Disease, 485–523. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08309-9_18.
Full text
10
Allen, K. J. "Haemochromatosis." In Oxford Textbook of Endocrinology and Diabetes, 1684–94. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.1258.
Full textAbstract:
Hereditary haemochromatosis is an inherited iron storage disorder in which altered iron metabolism leads to an increase in intestinal iron absorption. This results in a progressive accumulation of body iron stores particularly in the liver, heart, pancreas, and pituitary. The excess iron deposited in tissues may result in cirrhosis, diabetes, cardiac failure and arrhythmias, hypogonadism, arthritis, hepatocellular carcinoma, and a shortened life expectancy.
Conference papers on the topic "Diabetes Iran"
1
"Common Signs and Symptoms in Patients with Type II Diabetes in Iran." In International Institute of Chemical, Biological & Environmental Engineering. International Institute of Chemical, Biological & Environmental Engineering, 2015. http://dx.doi.org/10.15242/iicbe.c0615090.
Full text
2
Mozaffari, Abolfazl, and Maryam Hendiani. "Study on prevalence and associated factors of Diabetes Mellitus among Tuberculosis Patients in Iran." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2971.
Full text
3
"Diet History in Patients with Type1 and Type 2 Diabetes in Eslamshahr-Tehran, Iran." In International Conference on Food, Biological and Medical Sciences. International Institute of Chemical, Biological & Environmental Engineering, 2014. http://dx.doi.org/10.15242/iicbe.c0114602.
Full text
4
Aghniya, Rofana, Bhisma Murti, Didik Gunawan Tamtomo, and Hanung Prasetya. "The Effect of Depression Comorbidity on the Quality of Life of Patients with Type 2 Diabetes Mellitus: Meta-Analysis." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.01.56.
Full textAbstract:
Background: The prevalence of depression is two to three times higher in diabetic patients, while most cases remain undiagnosed. The quality of life is substantially and adversely affected by depression. This study aimed to estimate the effect of depression comorbidity on patients’ quality of life with type 2 diabetes mellitus. Subjects and Method: This was a meta-analysis and systematic review. The study was conducted by collecting published articles from PubMed, ProQuest, Science Direct, Scopus, Spinger Link, Clinical Key, and Google Scholar databases. Keywords used “comorbidity depression and DM”, “depression and quality of life and DM and cross sectional study”, “depression and quality of life and DM and adjusted odd ratio”, “depression or diabetes”, “depression or quality of life or DM or adjusted odd ratio”. The study criteria were full text, using cross-sectional study design, and reporting adjusted Odds Ratio (aOR). The selected articles were analyzed using Revman 5.3 with fixed effect models. Results: 8 studies from Uganda, Iran, United States, United Kingdom, Australia, Nigeria, Brazil, and Nepal, were selected for this study. Current study reported that type 2 DM patients with depression had lower quality of life than those without depression (aOR= 2.72; 95% CI= 0.73 to 10.07; p<0.0001) Conclusion: Type 2 DM patient with depression has lower quality of life than those without depression. Keywords: depression, quality of life, diabetes mellitus Correspondence: Rofana Aghniya. Masters Program in Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Central Java. Email: rofanaaa@gmail.com. Mobile: +685523528340.
5
"Familial History and Psychological Problems: High Risk Factors for Type 2 Diabetes in Hamedan (Northwestern Iran)." In International Conference on Chemical, Agricultural and Medical Sciences. International Institute of Chemical, Biological & Environmental Engineering, 2014. http://dx.doi.org/10.15242/iicbe.c514079.
Full text
6
"Glutathione S-transferase M1 genotype polymorphisms and type 2 diabetes risk in Zoroastrian female in Yazd, Iran." In International Conference on Medicine, Public Health and Biological Sciences. CASRP Publishing Company, Ltd. Uk, 2016. http://dx.doi.org/10.18869/mphbs.2016.104.
Full text
7
Babarykin, Dmitry, Gaļina Smirnova, Svetlana Vasiļjeva, Anna Fedotova, Andrey Fedotov, and Natālija Basova. "Evaluation of the biological activity of sugar-free fractionated red beetroot juice." In 80th International Scientific Conference of the University of Latvia. University of Latvia, 2023. http://dx.doi.org/10.22364/iarb.2022.05.
Full textAbstract:
In the case of type II diabetes, the most important preventive and therapeutic effect gives a diet with a minimal amount of easily digestible carbohydrates. Vegetable juices are posi-tioned as healthy food, because of the high content of phenolic and other biologically active compounds. However, due to the high glycemic index, juices are contraindicated in obesity, and diabetes, while juices with a reduced glycemic index, are not available on the market. We have developed a technology for the fractionation of red beetroot juice based on molecular mass using ultrafiltration. The resulting fraction stimulates the absorption of iron, increases blood hemoglobin level, and enhances capillary blood flow more effectively than native juice does. Both effects are important for patients with diabetes because the impaired blood supply to tissues and organs is an important pathogenetic factor in the development of diabetic renal failure, blindness, and gangrene. The sugar content in fractionated beetroot juice is 5–7%, which makes its use in diabetes problematic. The purpose of the study was to develop a technology for removing sugar from fractionated red beetroot juice and assessing the safety of its functional properties. The fractionated native red beetroot juice and fractionated fermented juice were studied. Fermentation was carried out using pre-activated yeast Saccharomyces cerevisiae. It was found that after 5-day fermentation, the sugar content in the fermented fractionated juice fell to 0.5–0.7%, while maintaining functional activity.
8
Ali, Rusul Arif Abd, Zahraa Kareem Al-Mayali, and Wijdan Rajh Hamza Al-Kraity. "Relation between iron status and hemoglobin in hepatitis patient with diabetes undergo hemodialysis." In 3RD INTERNATIONAL SCIENTIFIC CONFERENCE OF ALKAFEEL UNIVERSITY (ISCKU 2021). AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0067430.
Full text
9
Mahmood, Shukur, Majid Maatook, and Dhaigham Aatwan. "Risk Factors of Glycaemia Control among Children and Adolescents with Type 1 Diabetes in Basra City/Iraq." In Proceedings of 2nd International Multi-Disciplinary Conference Theme: Integrated Sciences and Technologies, IMDC-IST 2021, 7-9 September 2021, Sakarya, Turkey. EAI, 2022. http://dx.doi.org/10.4108/eai.7-9-2021.2314899.
Full text
10
Istepanian, Robert S. H., Alaa Mousa, Nazar Haddad, Ala Sungoor, Thamer Hammadan, Handrean Soran, and Turki Al-Anzi. "The potential of m-health systems for diabetes management in post conflict regions a case study from Iraq." In 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2014. http://dx.doi.org/10.1109/embc.2014.6944414.
Full text